The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Mebeverine hydrochloride 135 mg Film-coated Tablets

Azure Pharmaceuticals LtdPA22871/006/001

Main Information

Trade NameMebeverine hydrochloride 135 mg Film-coated Tablets
Active SubstancesMebeverine hydrochloride
Dosage FormFilm-coated tablet
Licence HolderAzure Pharmaceuticals Ltd
Licence NumberPA22871/006/001

Group Information

ATC CodeA03AA04 mebeverine


License statusAuthorised
Licence Issued22/11/2019
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back